AbbVie (ABBV): biotech and rate exposure
How global shocks reach ABBV
AbbVie is filed under Biotechnology, and 5 of the 6 shock types GLOBLVIEW tracks reach it through that sector (oil shock, conflict risk, chip/export, trade/tariff, rates/fed). Stories centered on the United States also register as geographic exposure, because AbbVie is registered in the United States.
| Shock | Channel | Tendency for ABBV | Why |
|---|---|---|---|
| OIL SHOCK | Input costs | ▼ tends to be pressured | Direct energy use is a small cost for biotechnology. Higher oil prices reach it through weaker demand and higher rates, not through input costs. |
| CONFLICT RISK | Risk appetite | ▼ tends to be pressured | Rising conflict risk tends to weigh on biotechnology, since investors trim exposure to anything read as discretionary or growth-dependent. |
| CHIP/EXPORT | Rules and access | ▼ tends to be pressured | Tighter export and chip rules tend to hurt biotechnology, cutting off supply, customers, or both. |
| TRADE/TARIFF | Revenue exposure | ▼ tends to be pressured | New tariffs tend to raise costs or shrink markets for biotechnology, since it depends on cross-border supply chains or sales. |
| RATES/FED | Price of money | ▼ tends to be pressured | Higher rates tend to pressure biotechnology, because expected profits sit further out and get discounted harder. |
Direction is a tendency across cycles, not a forecast. Sector mapping uses the Finnhub industry classification; geography uses country of registration, not revenue by region.
What actually moves AbbVie
Rates are a refinancing fact, not a demand fact. AbbVie carried about $67.5 billion of debt at the end of 2025, mostly fixed, with about $8.56 billion due within 12 months, including $6.0 billion of notes maturing in 2026. Swaps convert only $1.8 billion to floating. A policy-rate headline moves the shares long before it moves most of the coupon.
Trade is muted for now by a deal, not by the business being domestic. The United States was 76% of net revenues. In January 2026 AbbVie signed a voluntary agreement with the US government: pricing concessions and US investment in exchange for a three-year exemption from tariffs and future pricing mandates. A drug-pricing headline reaches the income statement more directly than a tariff headline during that window.
The less obvious concentration is the wholesale channel. Three distributors, McKesson, Cardinal Health and Cencora, accounted for substantially all US pharmaceutical sales, and no single one exceeded 43% of US gross revenues. Credit stress at those wholesalers is a collections issue. Skyrizi and Rinvoq together were about 42% of net revenues, so the book is also a two-product story that a rates or trade label will not name.
Drawn from the annual filing cited below. Not a forecast and not investment advice.
What AbbVie sells and where it earns
AbbVie sells prescription drugs and aesthetic products and reports as a single segment. Net revenues were $61.16 billion in 2025, up from $56.33 billion. Immunology is the largest area. Skyrizi brought in $17.56 billion, or 29% of revenue, and Rinvoq $8.30 billion, or 14%; the filing puts the two together at about 42% of net revenues. Humira, once its biggest product, fell 49% to $4.54 billion because of direct biosimilar competition after it lost exclusivity, and is now 7%. Botox, sold for both therapeutic and cosmetic use, totaled $6.37 billion, or 10%, though Botox Cosmetic fell 10.6% in the US. Vraylar, a psychiatric drug, was $3.62 billion, or 6%. Everything else, including the cancer drugs Imbruvica and Venclexta and the Juvederm fillers, made up the remaining 34%. The business is mostly domestic. The United States produced $46.60 billion, or 76% of net revenues, and the rest of the world 24%. Medicare price setting now reaches named products: Imbruvica from January 1, 2026, Vraylar and Linzess from 2027 and Botox from 2028.
Customer concentration
The 10-K says "three wholesale distributors (McKesson Corporation, Cardinal Health, Inc. and Cencora, Inc.) accounted for substantially all of AbbVie's pharmaceutical product sales in the United States" in 2025, and no single wholesaler exceeded 43% of US gross revenues. AbbVie also says it has no single customer whose loss would have a material adverse effect.
Debt
AbbVie carried about $67.5 billion of debt at December 31, 2025: $65.0 billion of long-term debt and finance leases ($64.50 billion of principal) plus $2.50 billion of short-term borrowings, a $2.0 billion 364-day term loan and $499 million of commercial paper. About $8.56 billion is due within 12 months, including $6.0 billion of notes maturing in 2026. The senior notes and the $2.0 billion term loan due April 2027 are fixed rate, and swaps convert only $1.8 billion of that to floating.
Risk factors that moved this year
- Most-favored-nation pricing is a new risk factor. The filing says governments may set drug prices by reference to international prices, and that in January 2026 AbbVie signed a voluntary agreement with the US government giving pricing concessions and US research and capital investment in exchange for a three-year exemption from tariffs and future pricing mandates.
- Medicare price setting keeps widening. Botox was selected in January 2026 for government-set prices in Medicare Parts B and D starting in 2028, joining Imbruvica (2026) and Vraylar and Linzess (2027), and the company warns that more high-revenue products could be picked and lose revenue before their patents expire.
- Pharmacy benefit managers get their own risk factor for the first time. AbbVie says consolidation among PBMs and other intermediaries has raised their power over formulary placement and rebates, and that government-mandated changes to PBM rebate practices could alter its contracts.
How this changes the exposure read
A pharma template treats AbbVie as defensive, and on demand that holds. Its real shocks are policy shocks. Trade/tariff risk is muted for now because the January 2026 agreement exempts it from tariffs for three years, so a drug-pricing headline matters more than a tariff headline. Oil shocks barely reach it. Rates/Fed matter through about $67.5 billion of mostly fixed-rate debt and $8.56 billion due within a year. Credit stress would show up through the three wholesalers that handle substantially all US drug sales. Conflict risk and chip/export rules are minor, limited to global sourcing of active ingredients.
Source: AbbVie 10-K, FY2025. Checked 2026-10-07. Figures are from the filing and may differ from the live stats above.
What is moving it now
Key stats
Recent filings
Related tickers
- What a central bank rate decision means for your holdings
- When a rate move reaches the cash
- Conflict headlines that cut both ways
- Shipping chokepoints and what they do to equities
- Sanctions and export controls are not tariffs
- Methodology and editorial policy
Quotes may be delayed. Information only, not investment advice.